News | November 13, 2013

WAVE I, WAVE II Studies of Renal Denervation Therapy Show Improvements in Hypertension

Kona Surround Sound technology utilizes externally delivered ultrasound to treat drug-resistant hypertension

November 13, 2013 — Petr Neuzil, M.D., Nemocnice Na Homolce Hospital, Prague, Czech Republic, presented three-month results from the WAVE II study and complete six-month results for the WAVE I (first-in-man) at the Transcatheter Cardiovascular Therapeutics conference (TCT 2013). Data from WAVE II demonstrated that resistant hypertension patients treated with the Surround Sound Renal Denervation System experienced a 19.4 mmHg drop in systolic blood pressure and 6.5 mmHg drop in diastolic blood pressure at three months (n = 17). For WAVE I, patients experienced blood pressure reductions of 22 / 9 mmHg at three months and 29 / 12 mmHG at six months (n = 24). For the combined studies, 73 percent of patients experienced a clinically significant drop in systolic blood pressure of 10 mmHg or more at three months and 81 percent at six months. There were no device related serious adverse events in WAVE I or WAVE II.
 
WAVE II utilizes a dosing pattern that reduces therapy delivery time from 13 minutes per patient side to less than three minutes when compared with WAVE I. 
 
The study sponsor, Kona Medical, also announced the initiation of the WAVE III study. WAVE III is evaluating the use of non-invasive ultrasound imaging to guide externally delivered therapeutic ultrasound energy.
 
“Data from the WAVE I and WAVE II studies continue to indicate the effectiveness of external ultrasound as a method of renal denervation,” said Neuzil. “The great promise of this technology is the opportunity to treat hypertension patients outside the cath lab without the use of catheters, invasive instruments or radiation. We look forward to the future results from the WAVE III study.”
 
The clinical study group included St. Vincent’s Hospital in Melbourne, Australia  (Robert Whitbourn, M.D., primary investigator), Nemocnice Na Homolce Hospital, Prague, Czech Republic (Neuzil) and St. Anne’s Hospital, Brno, Czech Republic (Dr. Zdenek Starek, Primary Investigator). and Dr. Murray Esler, Baker Heart, Diabetes Institute and core lab director of norepinephrine.
 
For more information: www.konamedical.com

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init